Dr. Zhou, Xinhua (Dr. Joe Zhou) is the CEO of Genor Biopharma, a VP and the R&D head of Walvax Bio Group. He has been selected as a national expert of the TOP 1000 TALENTS program in China since 2010. Dr. Zhou also is a visiting professor teaching Master Degree Program in International Pharmaceutical Engineering Management (IPEM) at Peking University, China. He is an invited vice-chair of Biopharmaceuticals Committee under China Pharmaceuticals Society, the Founder and first Chair of China Protein Drug Quality Alliance (CPDQA), the Founder and first Chair of Biological Drug Product and Process Committee of China ISPE, and the Founder and first Chair of Amgen Aluminums Association (AAA) in China. Previously, Dr. Zhou was Scientific Director at Amgen for bioprocess development and trouble shooting for bioprocess and bio-manufacturing. He has over 20-years industrial experience of process development, multiple project management capacity in cGMP and non-GMP reproducible purification/production of protein/antibody therapeutics from FIH to CPD with depth knowledge of CHO clone selection, cell culture optimization, viral clearance, real time analytical assays, formulation and product specification for drug substances and drug products.
Phar-East Day One @ 09:40
The Macro View: What will it take for Asia’s biotech industry to really flourish?Everyone knows it is too generic to classify all Asian countries in a single category. With the exception of China and India, the remaining part of Asia is complicated, fragmented and diversified. With growing GDPs and middle class populations, the potential of Asia’s biotech industry is undeniable in the eye of global leaders. The main question is, how can government and related stakeholders assist the biotech industry to flourish to provide more affordable, personalised medicine for its populations? How do countries move away from a “me-too” to “me-first” mentality, especially when it comes to pharma R&D?
Phar-East Day One @ 11:00
mAb Industry in China: Biosimilars vs. Innovative Biologics
Following patent cliffs for Erbitux, Rituxan, Sandosta_n and several big blockbusters, Herceptin, Avastin are now among the next biosimilar targets. This is creating huge potential for biosimilars, prompting innovators to shift their focus to target more emerging markets which remain untapped for many companies. In this presentation, Joe will be sharing with you his vision of the biosimilars market with a focus on China. He will also discuss key considerations for mAb and biologics therapeutic development, providing a broad overview of challenges and opportunities presenting in the market.
1. Landscape changes of mAb therapeutics
2. New targets and process/manufacturing innovation
3. Key consideration of mAb industry in China
4. Case study: Development strategies of PD-1 mAb as anti-tumor therapeutics in China for global market